ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ESSA Pharma Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Retained Earnings
-$208m
CAGR 3-Years
-21%
CAGR 5-Years
-29%
CAGR 10-Years
-46%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Retained Earnings
-CA$7.6m
CAGR 3-Years
-168%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Retained Earnings
-$409.1m
CAGR 3-Years
-8%
CAGR 5-Years
-9%
CAGR 10-Years
-5%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Retained Earnings
-$938m
CAGR 3-Years
-9%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
Covalon Technologies Ltd
XTSX:COV
Retained Earnings
-CA$36.3m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Spectral Medical Inc
TSX:EDT
Retained Earnings
-CA$142.6m
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
-12%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Retained Earnings?
Retained Earnings
-208m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Retained Earnings amounts to -208m USD.

What is ESSA Pharma Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-46%

Over the last year, the Retained Earnings growth was -16%. The average annual Retained Earnings growth rates for ESSA Pharma Inc have been -21% over the past three years , -29% over the past five years , and -46% over the past ten years .

Back to Top